AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16178655 — intervention group
Group type: COMPARATOR
Intervention: Normal colon mucosa/submucosa
Number of subjects: 0
Study 16178655 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenomatous colon mucosa/submucosa
Number of subjects: 0
Study 16178655 — intervention group
Group type: COMPARATOR
Intervention: Normal colon muscle layer/chorion
Number of subjects: 0
Study 16178655 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenomatous colon muscle layer/chorion
Number of subjects: 0
Study 14641990 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg or 500 mg daily) in combination with carboplatin/paclitaxel
Number of subjects: 0
Study 14641990 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg or 500 mg daily) in combination with cisplatin/gemcitabine
Number of subjects: 0
Study 10385666 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus interferon (CIFN) or interferon (IFN) alfa‐2b for 6 months
Number of subjects: 472
Study 8875441 — intervention group
Group type: COMPARATOR
Intervention: Sleep deprivation group (16 subjects)
Number of subjects: 32
Study 8875441 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeping group (16 subjects)
Number of subjects: 32
Study 8875441 — intervention group
Group type: COMPARATOR
Intervention: Age as a predictor in sleep-deprived subjects
Number of subjects: 32
Study 8875441 — intervention group
Group type: COMPARATOR
Intervention: Subjective sleepiness and drowsiness measures
Number of subjects: 32
Study 1686851 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 10
Study 1686851 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 10
Study 1686851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6336891 — intervention group
Group type: EXPERIMENTAL
Intervention: Orgotein (4 mg a week for six weeks)
Number of subjects: 28
Study 6336891 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone acetate (4 mg a week for six weeks)
Number of subjects: 28
Study 6336891 — intervention group
Group type: EXPERIMENTAL
Intervention: Orgotein
Number of subjects: 28
Study 30617724 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium monensin (MON; Rumensin® 200, Elanco Animal Health, Brazil) @ 0.6 mg/kg of body weight for 90 days
Number of subjects: 100
Study 30617724 — intervention group
Group type: COMPARATOR
Intervention: Total mixed ration without supplementation (CON)
Number of subjects: 100
Study 30047502 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 225
Study 30047502 — intervention group
Group type: COMPARATOR
Intervention: Conventional evidence-based therapy
Number of subjects: 225
Study 27319407 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage once per week for 8 weeks
Number of subjects: 59
Study 27319407 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 59
Study 24510512 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark roast coffee blend
Number of subjects: 9
Study 24510512 — intervention group
Group type: COMPARATOR
Intervention: Market blend coffee
Number of subjects: 9
Study 21885990 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term statin pretreatment (3-7 days) with rosuvastatin (hydrophilic statin)
Number of subjects: 0
Study 21885990 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term statin pretreatment (3-7 days) with atorvastatin (lipophilic statin)
Number of subjects: 0
Study 21885990 — intervention group
Group type: COMPARATOR
Intervention: Ischemia and reperfusion (IR)
Number of subjects: 0
Study 19280548 — intervention group
Group type: EXPERIMENTAL
Intervention: 22G IVC
Number of subjects: 91
Study 19280548 — intervention group
Group type: EXPERIMENTAL
Intervention: 20G IVC
Number of subjects: 91
Study 19280548 — intervention group
Group type: COMPARATOR
Intervention: In vitro testing
Number of subjects: 91
Study 19280548 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo testing
Number of subjects: 91
Study 17591488 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-scanning confocal microscopy (LCM)
Number of subjects: 15
Study 15365307 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (titrated to 50 mg/day)
Number of subjects: 215
Study 15365307 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene (titrated to 40 mg/day)
Number of subjects: 215
Study 15365307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 15365307 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.4 mg/kg for men, 0.34 mg/kg for women)
Number of subjects: 215
Study 11407649 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg sc)
Number of subjects: 25
Study 11407649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9739219 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision technique
Number of subjects: 40
Study 9739219 — intervention group
Group type: COMPARATOR
Intervention: Two-incision technique
Number of subjects: 40
Study 9739219 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 40
Study 7528949 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (Trasylol)
Number of subjects: 55
Study 7528949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 2499036 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (Aza)
Number of subjects: 80
Study 2499036 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 80
Study 2499036 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion from CsA to Aza
Number of subjects: 80
Study 29495908 — intervention group
Group type: EXPERIMENTAL
Intervention: Long noncoding RNA (lncRNA) expression levels in endometrium
Number of subjects: 50
Study 29495908 — intervention group
Group type: COMPARATOR
Intervention: Control women
Number of subjects: 50
Study 29056121 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel clipless group (HSG)
Number of subjects: 150
Study 29056121 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (CLC) with electrocautery group
Number of subjects: 150
Study 24611630 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates course (12 weeks)
Number of subjects: 96
Study 24611630 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 96
Study 23482762 — intervention group
Group type: EXPERIMENTAL
Intervention: PapCone® sampling method
Number of subjects: 18
Study 23482762 — intervention group
Group type: COMPARATOR
Intervention: Conventional sampling method (Ayre's spatula plus cytobrush)
Number of subjects: 18
Study 21808115 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleural tubes inserted through the sixth intercostal space at the midaxillary line (IC6, n=20)
Number of subjects: 60
Study 21808115 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid straight pleural tubes inserted from the mediastinum through the subxiphoid area (SX‐r, n=20)
Number of subjects: 60
Study 21808115 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft curved drainage tubes inserted from the mediastinum through the subxiphoid area (SX‐s, n=20)
Number of subjects: 60
Study 21808115 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 60
Study 19715976 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) with stepwise reduction of CNI
Number of subjects: 90
Study 19715976 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintenance CNI dose)
Number of subjects: 90
Study 17013995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen-arginine (400 mg)
Number of subjects: 20
Study 17013995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17013995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen-arginine
Number of subjects: 20
Study 12881035 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretest as a covariate in the model
Number of subjects: 0
Study 12881035 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttest and follow-up analysis
Number of subjects: 0
Study 11021450 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncemented fixation
Number of subjects: 28
Study 11021450 — intervention group
Group type: COMPARATOR
Intervention: Cemented fixation
Number of subjects: 28
Study 8795673 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous flow oxygen
Number of subjects: 15
Study 8795673 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand oxygen delivery system (DODS)
Number of subjects: 15
Study 1618199 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian pattern of MI incidence
Number of subjects: 12163
Study 1618199 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian pattern of MI incidence in diabetics
Number of subjects: 12163
Study 6360786 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-micrograms doses of 15-R-15 methyl prostaglandin E2 for 24 h before treatment with aspirin
Number of subjects: 30
Study 6360786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31120674 — intervention group
Group type: EXPERIMENTAL
Intervention: Vatinoxan (117-297 μg/kg)
Number of subjects: 8
Study 31120674 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 8
Study 30538080 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold application to median nerve at wrist
Number of subjects: 15
Study 30538080 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cold application)
Number of subjects: 15
Study 26923088 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Bone Regeneration (GBR)
Number of subjects: 22
Study 26923088 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous Healing (SH)
Number of subjects: 22
Study 26923088 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 26350482 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive safety decision aid web-based and smartphone application (App) for abused college women and their friends
Number of subjects: 600
Study 26350482 — intervention group
Group type: COMPARATOR
Intervention: Usual safety planning control website/App
Number of subjects: 600
Study 23554974 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent Inactivated Influenza Vaccine (TIV)
Number of subjects: 0
Study 21382439 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Inclusion (SI)
Number of subjects: 55
Study 21382439 — intervention group
Group type: COMPARATOR
Intervention: Social Exclusion (SE)
Number of subjects: 55
Study 21382439 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (SI and SE)
Number of subjects: 55
Study 19398930 — intervention group
Group type: COMPARATOR
Intervention: Probiotic supplementation (preventive effects)
Number of subjects: 632
Study 19398930 — intervention group
Group type: COMPARATOR
Intervention: Probiotic supplementation (therapeutic role)
Number of subjects: 632
Study 17926616 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture TENS group
Number of subjects: 120
Study 17926616 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoints TENS group
Number of subjects: 120
Study 17926616 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) group
Number of subjects: 120
Study 17926616 — intervention group
Group type: COMPARATOR
Intervention: Non-abdominal acupuncture TENS group
Number of subjects: 120
Study 15276091 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria (n=28)
Number of subjects: 143
Study 15276091 — intervention group
Group type: COMPARATOR
Intervention: Normoalbuminuria (n=115)
Number of subjects: 143
Study 11844641 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (80 mg/kg)
Number of subjects: 0
Study 11844641 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (2.5 mM) in isolated rat heart
Number of subjects: 0
Study 11844641 — intervention group
Group type: COMPARATOR
Intervention: Glutamate (2.5 mM) in isolated rat heart
Number of subjects: 0
Study 11844641 — intervention group
Group type: COMPARATOR
Intervention: Aspartate (2.5 mM) in isolated rat heart
Number of subjects: 0
Study 9671862 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin, 2.5 mg three times daily for 3 months, followed by maintenance of alfuzosin
Number of subjects: 79
Study 9671862 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin, 2.5 mg three times daily for 3 months, followed by alfuzosin every other day
Number of subjects: 79
Study 9671862 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of alfuzosin (no treatment)
Number of subjects: 79
Study 7670424 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic thermography
Number of subjects: 18
Study 2659560 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysozyme
Number of subjects: 14
Study 31754852 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D TAPP laparoscopic approach
Number of subjects: 278
Study 31754852 — intervention group
Group type: COMPARATOR
Intervention: 2D TAPP laparoscopic approach
Number of subjects: 278
Study 29910120 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT + MRIGE (computerized social cognition training)
Number of subjects: 131
Study 29910120 — intervention group
Group type: COMPARATOR
Intervention: CRT alone
Number of subjects: 131
Study 29910120 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT + MRIGE
Number of subjects: 131
Study 28877729 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced feedback (monthly written feedback incorporating goal setting and action planning delivered by a senior clinical coordinator)
Number of subjects: 12
Study 28877729 — intervention group
Group type: COMPARATOR
Intervention: Standard feedback (2‐monthly written feedback on multiple quality of pediatric care indicators)
Number of subjects: 12
Study 27002696 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral therapy and surgical procedures
Number of subjects: 56
Study 27002696 — intervention group
Group type: COMPARATOR
Intervention: Dental treatment, local and systemic keratoplastic formulations
Number of subjects: 56
Study 23437816 — intervention group
Group type: EXPERIMENTAL
Intervention: Phantom shocks (PS)
Number of subjects: 17
Study 23437816 — intervention group
Group type: COMPARATOR
Intervention: Objective shocks only (OSO)
Number of subjects: 17
Study 21284476 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII/RT‐CGM with the algorithm (Group A)
Number of subjects: 60
Study 21284476 — intervention group
Group type: COMPARATOR
Intervention: CSII/RT‐CGM without algorithm (Group B)
Number of subjects: 60
Study 20035590 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow titration schedule, 1.4 mg/kg/day
Number of subjects: 267
Study 20035590 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow titration schedule, 0.8 mg/kg/day
Number of subjects: 267
Study 20035590 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast titration schedule, 1.4 mg/kg/day
Number of subjects: 267
Study 20035590 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast titration schedule, 0.8 mg/kg/day
Number of subjects: 267
Study 20035590 — intervention group
Group type: EXPERIMENTAL
Intervention: Both maintenance treatment groups (0.8 mg/kg/day and 1.4 mg/kg/day)
Number of subjects: 267
Study 16498932 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiologically guided technique (group 2)
Number of subjects: 80
Study 16498932 — intervention group
Group type: COMPARATOR
Intervention: Anatomical landmark method (group 1)
Number of subjects: 80
Study 15162466 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2Rab (basiliximab) 20 mg intravenously within 6 hours of graft reperfusion and on postoperative day 4
Number of subjects: 31
Study 15162466 — intervention group
Group type: COMPARATOR
Intervention: Steroid group (standard immunosuppressive regimen with tacrolimus and corticosteroid), n = 49
Number of subjects: 31
Study 10985600 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training Group (ATG)
Number of subjects: 48
Study 10985600 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training Group (RTG)
Number of subjects: 48
Study 10985600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-Training Group (XTG)
Number of subjects: 48
Study 10985600 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 48
Study 9568337 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone iodine plus neosporin (PVP + N)
Number of subjects: 1053
Study 9568337 — intervention group
Group type: COMPARATOR
Intervention: Silver sulphadiazine (SSD)
Number of subjects: 1053
Study 8403178 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine-lidocaine mixture, pH 6.7 with hyaluronidase (10 units.ml-1)
Number of subjects: 100
Study 8403178 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine-lidocaine mixture, pH 3.9
Number of subjects: 100
Study 8403178 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine-lidocaine mixture with hyaluronidase, pH 5.1
Number of subjects: 100
Study 8403178 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine-lidocaine mixture alkalinized to pH 5.1
Number of subjects: 100
Study 8403178 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine-lidocaine mixture alkalinized to pH 6.7
Number of subjects: 100
Study 6752875 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirprofen 800 mg/day
Number of subjects: 183
Study 6752875 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen 300 mg/day
Number of subjects: 183
Study 31512550 — intervention group
Group type: EXPERIMENTAL
Intervention: Night Time Recharge (NTR)
Number of subjects: 20
Study 31512550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27785747 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic alkali therapy
Number of subjects: 200
Study 27785747 — intervention group
Group type: COMPARATOR
Intervention: No chronic alkali therapy
Number of subjects: 200
Study 27785747 — intervention group
Group type: COMPARATOR
Intervention: Healthy male age-matched volunteers
Number of subjects: 200
Study 24917531 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal abdominal hysterectomy (SAH)
Number of subjects: 319
Study 24917531 — intervention group
Group type: COMPARATOR
Intervention: Total abdominal hysterectomy (TAH)
Number of subjects: 319
Study 23675985 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation (100 mJ, 85 J/cm² per pulse with a quartz fiber of 400 μm, in scanning movements)
Number of subjects: 48
Study 23675985 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office prophylaxis with pumice
Number of subjects: 48
Study 23675985 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office Colgate Sensitive Pro-Relief™ Desensitizing Paste
Number of subjects: 48
Study 23675985 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 48
Study 21402619 — intervention group
Group type: EXPERIMENTAL
Intervention: C-PLD (carboplatin-pegylated liposomal doxorubicin)
Number of subjects: 157
Study 21402619 — intervention group
Group type: COMPARATOR
Intervention: C-P (carboplatin-paclitaxel)
Number of subjects: 157
Study 21402619 — intervention group
Group type: EXPERIMENTAL
Intervention: C-PLD
Number of subjects: 157
Study 21402619 — intervention group
Group type: COMPARATOR
Intervention: C-P
Number of subjects: 157
Study 19541594 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (IL-1 receptor antagonist)
Number of subjects: 5
Study 19541594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 16953366 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-alanine plus creatine (CrBA)
Number of subjects: 55
Study 16953366 — intervention group
Group type: EXPERIMENTAL
Intervention: creatine (Cr)
Number of subjects: 55
Study 16953366 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-alanine (beta-Ala)
Number of subjects: 55
Study 16953366 — intervention group
Group type: COMPARATOR
Intervention: placebo (PL)
Number of subjects: 55
Study 16966687 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus carboplatin
Number of subjects: 356
Study 16966687 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 356
Study 16966687 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 356
Study 12937009 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (CFC) 20 mg/kg
Number of subjects: 67
Study 12937009 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid (AMX/CA) 20 mg/kg (4:1 ratio)
Number of subjects: 67
Study 10321661 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (loading dose of 100 mg followed by continuous infusion of 0.18 mg/kg/hr, reduced to 0.08 mg/kg/hr after shock reversal)
Number of subjects: 40
Study 10321661 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiologic saline solution)
Number of subjects: 40
Study 7577590 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 0.05% cream applied once-daily
Number of subjects: 270
Study 7577590 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 0.05% cream applied twice-daily
Number of subjects: 270
Study 7577590 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 0.05% cream applied once-daily with vehicle cream
Number of subjects: 270
Study 7577590 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 0.05% cream applied once-daily and twice-daily
Number of subjects: 270
Study 1836679 — intervention group
Group type: EXPERIMENTAL
Intervention: Lordotic posture facilitated by a lumbar roll
Number of subjects: 210
Study 1836679 — intervention group
Group type: COMPARATOR
Intervention: Kyphotic posture facilitated by a flat foam cushion
Number of subjects: 210
Study 7042373 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol/hydrochlorothiazide
Number of subjects: 34
Study 7042373 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol/hydralazine/hydrochlorothiazide
Number of subjects: 34
Study 7042373 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol/hydralazine
Number of subjects: 34
Study 31181186 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 81
Study 31181186 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 81
Study 28109092 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative mechanical bowel preparation
Number of subjects: 148